TRIANA Biomedicines said on Thursday it had closed an oversubscribed $120 million Series B financing, strengthening its push to bring a new class of molecular glue degraders into the clinic, including its lead candidate, TRI-611, for patients with ALK-positive non-small cell lung cancer (NSCLC). The round was co-led by new investors (Ascenta Capital) and (Bessemer…
Junevity, a pioneering biotechnology company with the ambitious mission of extending human healthspan through advanced cell reprogramming, today announced it has successfully expanded its Seed financing to a total of $20 million with an additional $10 million investment. The new capital was jointly led by Goldcrest Capital and Godfrey Capital, providing the runway necessary to…
Aether Biomachines, an American artificial intelligence company focused on delivering real-world industrial solutions using AI-designed proteins, today announced it has raised an additional $15 million in funding. The round was led by Tribe Capital, with significant participation from both new and existing investors, including Natural Capital, Henkel Corporation, Resilience Reserve, Shrug Capital, 4DX Ventures, Unless…
Rapafusyn Pharmaceuticals, a trailblazer in the realm of therapeutic drug discovery, has announced a significant milestone with the closure of a Series A financing round, amassing $28 million. This strategic investment round was led by 3E Bioventures Capital and Proxima Ventures Ltd., with participation from Lapam Capital. Rapafusyn is spearheading the development of non-degrading molecular…
